The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of biologic therapy in phase II breast cancer clinical trials.
K. Patel
No relevant relationships to disclose
A. Kamal
No relevant relationships to disclose
T. Zhang
No relevant relationships to disclose
A. Schneider
No relevant relationships to disclose
E. P. Hamilton
No relevant relationships to disclose
J. M. Peppercorn
Employment or Leadership Position - GlaxoSmithKline (I)
Consultant or Advisory Role - AVEO; Bayer; Novartis
Honoraria - Genentech; Novartis
Research Funding - Novartis